CClinicalTrials.gg
CompletedNCT06409546Updated May 10, 2024

Impact of Topical Pentoxifylline and Tocopherol in Treatment and Prevention of Medically-related Osteonecrosis of the Jaws

An interventional study of Tocopherol and pentoxifilline topical gel and Placebo in Medically Related Osteonecrosis of the Jaws, sponsored by University of Catania. Completed at 1 site in Italy. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by University of Catania · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 1 month after the study started (first participant enrolled Apr 2020, registered May 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

While there is no doubt about the benefits of antiresorptives, it is known that patients using these drugs are at increased risk of developing osteonecrosis of the jaws (MRNOJ), especially after oral procedures such as tooth extraction. The management of osteonecrosis has remained a controversial topic within the oral and maxillofacial surgery community.

The aim of the present study is to analyze the impact of topical pentoxifilline and tocopherol in the prevention and treatment of MRNOJ.

Read the detailed description

A double-blind randomized controlled clinical trial is conducted in order to evaluate the impact of topical pentoxifilline and tocopherol in the prevention and treatment of MRNOJ and determine the statistical significance of the outcome variables.

48 subjects with MRNOJ, randomly allocated in two groups: placebo group with a 4% hydroxyethyl cellulose adhesive gel and the treatment group with the same gel containing pentoxifilline 5% and tocopherol 75%.

02

Conditions studied

  • Medically Related Osteonecrosis of the Jaws

Browse trials for

03

In context

Osteonecrosis

184 studies on the registry are indexed under Osteonecrosis; 33 are open to participants now.

This study's enrollment of 48 is close to the median of 51 across 98 interventional studies indexed under Osteonecrosis.

Browse Osteonecrosis studies →

Lead sponsor

University of Catania is the lead sponsor of 68 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Correspondence to the updated SIPMO criteria for MRONJ diagnosis
  • Need for tooth extraction

Exclusion criteria

Exclusion Criteria:

  • Recent use of antibiotics and anti-inflammatories in the last 4 weeks
  • Oral lesions of hard and soft tissues not related to MRONJ
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Tocopherol 75% and pentoxifilline 5% gel

    Patients treated with a topical gel of tocopherol 75% and pentoxifilline 5%

    Drug: Tocopherol and pentoxifilline topical gel

  • Placebo comparator
    Placebo gel

    Patients treated with a topical placebo gel control

    Drug: Placebo

Interventions

  • DrugTocopherol and pentoxifilline topical gel

    Oral gel applied locally on the MRONJ related lesions or post-extraction sockets

  • DrugPlacebo

    Oral gel applied locally on the MRONJ related lesions or post-extraction sockets

06

What researchers measure

Primary outcomes

  1. Oral Health Impact Profile Short Form (OHIP-14)

    4-point scale in which the presence or absence of physical pain, functional limitation, psychological distress, physical, psychological and social disability and handicap is analyzed

    Time frame: 6 months

Secondary outcomes

  1. Alveolar bone resorption

    Amount of vertical alveolar resorption expressed in mm

    Time frame: 6 months

07

Study locations

1 site
  • AOU Policlinico G. Rodolico
    Catania, CT 95124, Italy
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06409546
Lead sponsor
University of Catania
Responsible party
Gaetano Isola (Researcher, University of Catania) — Principal investigator
First posted
May 10, 2024
Start date
Apr 2, 2020
Primary completion
Dec 17, 2023
Completion
Jan 24, 2024
Last update
May 10, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion